Peripheral blood DNA methylation signatures predict response to vedolizumab and ustekinumab in adult patients with Crohn’s disease: The EPIC-CD study

Abstract

Biological therapeutics are now widely used in Crohn’s disease (CD), with evidence of efficacy from randomized trials and real-world experience. Primary non-response is a common, poorly understood problem. We assessed blood methylation as a predictor of response to vedolizumab (VDZ, anti-a4b7 integrin) or ustekinumab (USTE, anti-IL-12/23p40). We report a two-center, prospective cohort study in which we profiled the peripheral blood DNA methylome of 184 adult male and female CD patients prior to and during treatment with VDZ or USTE in a discovery (n=126) and an external validation cohort (n=58). We defined epigenetic biomarkers that were stable over time and associated with combined clinical and endoscopic response to VDZ or USTE with an area under curve (AUC) of 0.87 and 0.89, respectively. We validated these models in an external cohort yielding an AUC of 0.75 for both VDZ and USTE. These data will now be prospectively tested in a multicenter randomized clinical trial.

• Download figure
• Open in new tab

Competing Interest Statement

The AmsterdamUMC has a patent pending for the vedolizumab and ustekinumab response prediction models presented in this manuscript. The remaining authors have no conflicts of interest to declare.

Funding Statement

This project was supported by a grant from the Helmsley Foundation [2019-1179].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The project was approved by the medical ethics committee of the Academic Medical Hospital (METC NL57944.018.16 and NL53989.018.15) and written informed consent was obtained from all subjects prior to sampling, as well as by the National Health Service Research Ethics committee (REC reference: 21/PR/0010 Protocol number: 14833 IRAS project ID: 266041). UK patients were recruited and consented under the ethics of the Translational Gastrointestinal Unit biobank IBD cohort ethics (09/H1204/30) and GI cohort ethics (16/YH/0247 and 21/YH/0206). The quality of the collected data and study procedures were assessed by an independent monitor.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes